Cefepime as Empirical Monotherapy in Febrile Patients with Hematological Malignancies and Neutropenia: A Randomized, Single-Center Phase II Trial

REFERENCES

• Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–8.
   PubMed Web of Science ®Google Scholar
• Sanders JW, Powe NR, Moor RD. Ceftazidime monotherapy for empiric treatment of neutropenic patients: a metaanalysis. J Infect Dis 1991; 164: 907–16.
   PubMed Web of Science ®Google Scholar
• De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly P. ceftazidime compared with piperacillin and tobramycin for empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994; 120: 834–44.
   PubMed Web of Science ®Google Scholar
• Leyland MJ, Bayston KF, Cohen J et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with hematological malignancies. J Antimicrob Chemother 1992; 30: 843–54.
   Google Scholar
• Rolston KVI, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283–91.
   Google Scholar
• Freifeld AG, Walsh T, Marshall D et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165–76.
   Google Scholar
• The Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherpay of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185–200.
   Google Scholar
• Engervall P, Björkholm M. Infections in neutropenic patients. Part I: Etiology. Med Oncol 1996; 12: 251–6.
   Web of Science ®Google Scholar
• Barradell LB, Bryson HM. cefepime. A review of its antibacterial activity, pharmacokinetic properties and thera-peutic use. Drugs 1994; 47: 471–505.
   Google Scholar
• Eggimann P, Glauser MP, Aoun M, Neunier F, Calandra T. cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 1993; 32 (Suppl. B): 151-63.
   Google Scholar
• Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996; 100 (suppl. 6A): 83S-9S.
   Google Scholar
• Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 1997; 41: 1704–8.
   PubMed Web of Science ®Google Scholar
• Engervall P, Stiernstedt G, Gunther G, Björkholm M. Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders. J Chemother 1992; 4: 99–106.
   PubMed Web of Science ®Google Scholar
• Engervall P, Gunther G, Ljungman P, et al. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever. Scand J Infect Dis 1996; 28: 297–303.
   PubMed Web of Science ®Google Scholar
• Swedish Reference Group for Antibiotics. Referens och metodbok. Resistensbestämning av bakterier mot antibiotika. In Swedish. 1990-1996.
   Google Scholar
• Baker CN, Stocker SA, Culver DH, Thornsberry C. Comparison of the E test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J din Microbiol 1991; 29: 533–8.
   Web of Science ®Google Scholar
• Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161: 397–401.
   PubMed Web of Science ®Google Scholar
• Kinsey SE, Machin SJ, Goldstone AH. ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. J Hosp Infect 1990; 15: 49–53.
   PubMed Web of Science ®Google Scholar
• Samuelson J, Lonnqvist B, Palmblad J, et al. ceftazidime as initial therapy in febrile patients with acute leukemia during induction chemotherapy. Scand J Infect Dis 1992; 24: 89–96.
   PubMedGoogle Scholar
• EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada - Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocy-topenic cancer patients. J Infect Dis 1991; 163: 951–8.
   Google Scholar
• Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not essential component of the initial empirical treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992; 36: 1062–7.
   PubMed Web of Science ®Google Scholar
• Compeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, De Pauw BE. Early identification of neutropenic patients at risk of gram-positive bacteremia and the impact of empirical administration of vancomycin. Eur J Cancer 1996; 32A: 1332–9.
   PubMed Web of Science ®Google Scholar
• Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16: 105–13.
   Google Scholar
• Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agent Chemother 1996; 40: 1108–15.
   PubMed Web of Science ®Google Scholar